Advanced Materials and Drug Delivery
The Advanced Materials and Drug Delivery Cluster Area seeks to create and apply cutting-edge biomaterials for high-impact biomedical applications and to create paradigm-changing approaches and systems for advanced drug delivery.
Novel biomaterials are created to solve critical issues of the field: guide tissue regeneration, design highly selective, robust and biocompatible sensors, and alter surface chemistry to improve tissue/device interfaces. Likewise, we thrive to deliver difficult drugs (proteins, peptides, siRNA, insoluble anticancer drugs, vaccine antigens) in a targeted manner and to hard-to- reach places (cancer cells, brain, eye, lymph nodes) for prolonged periods of time (controlled release) in order to maximize therapeutic efficacy.
Our efforts in biomaterials include designing novel polymer-protein and polymer lipid composites for sensing of influenza virus, prostate cancer antigen and antibiotics. Surface engineering of biomaterials can lead to creation of non-wettable surfaces to control protein and cell adhesion, stem cell culture and differentiation. We blend and modify biocompatible polymers to improve mucoadhesion and stability of entrapped drug molecules. We cross-link phospholipid bilayers and develop lipid-peptide complexes to alter cell processing of biomaterials. We collectively contributed to an extensive toolbox of drug delivery platforms such as mucoadhesive gels, biodegradable implants, multicompartmental polymer nanoparticles, cross-linked liposomes for antigen delivery, and lipoprotein nanodisks. These platform technologies deliver a wide range of drug molecules and vaccine antigens with a focus on large molecule stability and delivery.
Multi-phasic particles of different shapes can be manufactured with precise control over particles geometry by the Wettability Engendered Templated Self-assembly (WETS) method.